Oculis (NASDAQ:OCS) Sets New 52-Week High – Should You Buy?

Oculis Holding AG (NASDAQ:OCS) reached a new 52-week high on Friday . The company traded as high as $23.40 and last traded at $22.8690, with a volume of 67945 shares trading hands. The stock had previously closed at $22.03.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on OCS. Lifesci Capital began coverage on Oculis in a research report on Wednesday, December 3rd. They set an “outperform” rating and a $55.00 price target on the stock. Chardan Capital reissued a “buy” rating and set a $51.00 target price on shares of Oculis in a report on Tuesday, November 11th. Bank of America decreased their price target on Oculis from $30.00 to $29.00 and set a “buy” rating on the stock in a research report on Thursday, November 13th. Stifel Nicolaus upped their price objective on shares of Oculis from $35.00 to $40.00 and gave the stock a “buy” rating in a research report on Friday, December 19th. Finally, Needham & Company LLC reiterated a “buy” rating and set a $36.00 price objective on shares of Oculis in a research note on Tuesday, November 11th. Eight analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $41.50.

Oculis Trading Up 6.8%

The firm has a 50-day moving average of $19.84 and a two-hundred day moving average of $18.95. The firm has a market capitalization of $1.23 billion, a P/E ratio of -9.34 and a beta of 0.31. The company has a current ratio of 4.47, a quick ratio of 4.47 and a debt-to-equity ratio of 0.02.

Oculis (NASDAQ:OCS) last issued its earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.10. The firm had revenue of $0.31 million during the quarter, compared to the consensus estimate of $0.23 million. Oculis had a negative return on equity of 80.82% and a negative net margin of 12,915.42%. On average, analysts anticipate that Oculis Holding AG will post -2.09 EPS for the current year.

Hedge Funds Weigh In On Oculis

Several institutional investors and hedge funds have recently added to or reduced their stakes in OCS. Aventura Private Wealth LLC bought a new stake in shares of Oculis during the fourth quarter worth $80,000. Bosun Asset Management LLC bought a new position in shares of Oculis in the 2nd quarter valued at $378,000. Marshall Wace LLP acquired a new stake in shares of Oculis during the 2nd quarter valued at $393,000. Geode Capital Management LLC grew its position in Oculis by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after acquiring an additional 6,384 shares during the last quarter. Finally, Bank of America Corp DE grew its position in Oculis by 2.2% during the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock worth $786,000 after acquiring an additional 878 shares during the last quarter. Institutional investors own 22.30% of the company’s stock.

About Oculis

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.